Payment overview · 2025
General Payments
$165.82
8 reported records · 7 companies
Healthcare provider profile · identity verified
Brian Keith Albertson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine|Sports Medicine · TRAFALGAR, IN · NPI 1023173077
Verified facts
What the public records show
CMS Open Payments records show Brian Keith Albertson, M.D. received $165.82 in general payments during 2025 across 8 reported records.
Medtronic, Inc. accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Caplyta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$48.73 | 29.4% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.17 | 15.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.94 | 13.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.79 | 13.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.19 | 11.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.30 | 9.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.70 | 8.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $165.82 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $48.73 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.94 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 75 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
75 | 14 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 220 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 202 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 153 | 35 |
| Furosemide | Furosemide | 150 | 42 |
| Gabapentin | Gabapentin | 146 | 43 |
| Lisinopril | Lisinopril | 136 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 23 |
| Amlodipine Besylate | Amlodipine Besylate | 110 | 36 |
| Clonazepam | Clonazepam | 109 | 15 |
| Omeprazole | Omeprazole | 105 | 34 |
| Mounjaro | Tirzepatide | 89 | 14 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 22 |
| Metformin Hcl | Metformin Hcl | 77 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 75 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 75 | 14 |
| Prednisone | Prednisone | 71 | 29 |
| Trazodone Hcl | Trazodone Hcl | 71 | 18 |
| Ozempic | Semaglutide | 62 | suppressed |
| Eliquis | Apixaban | 59 | 13 |
| Alprazolam | Alprazolam | 58 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 17 |
| Jardiance | Empagliflozin | 55 | 16 |
| Potassium Chloride | Potassium Chloride | 55 | 20 |
| Meloxicam | Meloxicam | 54 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 12 |
| Tramadol Hcl | Tramadol Hcl | 53 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 50 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 48 | 12 |
| Spironolactone | Spironolactone | 46 | 13 |
| Metformin Hcl Er | Metformin Hcl | 45 | 15 |
| Allopurinol | Allopurinol | 44 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | 12 |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Diazepam | Diazepam | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 11 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Movantik | Naloxegol Oxalate | 38 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 37 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Losartan Potassium | Losartan Potassium | 36 | 13 |
| Montelukast Sodium | Montelukast Sodium | 35 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Atenolol | Atenolol | 32 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | 11 |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | 11 |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 28 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Simvastatin | Simvastatin | 27 | 12 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Caplyta | Lumateperone Tosylate | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 22 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Xtampza Er | Oxycodone Myristate | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $165.82 · 8 records | Medtronic, Inc. | CAPLYTA, FANAPT, MINIMED 780G, REXULTI, TRELEGY ELLIPTA, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error